StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) income statement

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$315.34+16.79 (+5.62%)

Close on Nov 18, 2026Market cap $9.33BP/E 39.5Yield –

Krystal Biotech, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
44.9%
Net margin
54.8%
Return on equity, FY2025
18.9%

Financial strength

Current ratio
8.32
Debt to equity
–
Debt to assets
–
Cash to current liabilities
335.8%

Valuation

P/E ratio
39.5
Price to sales
21.19
Price to book
6.87
Dividend yield
–

See a number that looks wrong?